Table 3. Trends of AF patients according to treatment patterns, morbidity and mortality.
Medications | Year | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | |
Stroke prevention | ||||||||||
Aspirin | 1359 (32.4) |
1757 (33.7) |
2051 (33.6) |
2411 (34.3) |
2689 (33.7) |
2928 (33.3) |
3197 (33.3) |
3498 (33.3) |
3769 (33.4) |
3868 (32.3) |
Other antiplatelet agents* † | 148 (3.5) |
194 (3.7) |
280 (4.6) |
445 (6.3) |
608 (7.6) |
805 (9.2) |
833 (8.7) |
953 (9.1) |
1147 (10.1) |
1361 (11.3) |
Warfarin | 764 (18.2) |
934 (17.9) |
1034 (16.9) |
1151 (16.4) |
1256 (15.7) |
1381 (15.7) |
1476 (15.4) |
1679 (16.0) |
1863 (16.5) |
2002 (16.7) |
Rate control | ||||||||||
Beta blocker* | 948 (22.6) |
1241 (23.8) |
1465 (24.0) |
1694 (24.1) |
1889 (23.7) |
2112 (24.1) |
2393 (24.9) |
2736 (26.1) |
3034 (26.8) |
3248 (27.1) |
Calcium channel blocker* | 322 (7.7) |
383 (7.3) |
452 (7.4) |
536 (7.6) |
598 (7.5) |
654 (7.4) |
673 (7.0) |
780 (7.4) |
830 (7.3) |
914 (7.6) |
Digoxin* | 980 (23.4) |
1121 (21.5) |
1153 (18.9) |
1194 (17.0) |
1170 (14.7) |
1219 (13.9) |
1206 (12.5) |
1327 (12.6) |
1351 (12.0) |
1367 (11.4) |
Rhythm control | ||||||||||
Number of patients* | 287 (6.8) |
333 (6.4) |
402 (6.6) |
453 (6.4) |
499 (6.2) |
570 (6.5) |
602 (6.3) |
745 (7.1) |
819 (7.2) |
916 (7.6) |
Class Ic* | 116 (2.8) |
146 (2.8) |
190 (3.1) |
224 (3.2) |
263 (3.3) |
301 (3.4) |
324 (3.4) |
418 (4.0) |
483 (4.3) |
566 (4.7) |
Class III* | 180 (4.3) |
201 (3.9) |
224 (3.7) |
247 (3.5) |
257 (3.2) |
285 (3.2) |
295 (3.1) |
349 (3.3) |
359 (3.2) |
378 (3.2) |
Hospitalization for RFCA‡ | 5 (0.43) | 4 (0.30) | 7 (0.01) | 3 (0.20) | 17 (1.01) | 19 (1.11) | 26 (1.41) | 19 (0.85) | 43 (1.71) | 30 (1.09) |
Values are presented as number (%). *p value for trends <0.05. †Includes clopidogrel, prasugrel, and ticagrelor. ‡Estimated by the proportion of hospitalization for RFCA out of total hospitalization number. RFCA: radiofrequency catheter ablation